Cannabinoids Role in Astroglial Tumors | cannabisMD

Cannabinoids Role in Astroglial Tumors

Astroglial Tumors - Role of Cannabinoids

Image Credit: Giovanni Cancemi on Shutterstock

An astroglial tumor is a group of tumours related to the astroglial cells. They are one of the most common and are accountable for more than 60% of primary brain tumors. Studies are underway and are debating whether or not cannabinoids could prevent the initial growth of the tumors.

So far, we know that with the help of cannabinoids, they could have the potential of easing pain for those with; epilepsy, cancer, multiple sclerosis, parkinsons disease and arthritis.

This paper will look at how cannabinoids can be used to fight human astroglial tumors.

Here is the full scientific article if you wish to download it.

Cannabinoids Are Beneficial in Human Glioma Cells

In animal studies, cannabinoids are said to prevent the growth of tumors, including gliomas. These effects have been said to be controlled via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, researchers delved into receptor subtype expression in surgical material of solid human astrocytomas, gliomas and cultivated glioma cells. In a normal brain, cultivated glioma cells and solid tumors, CB1 mRNA was expressed to a much higher extent than CB2, which in some solutions was nowhere to be seen. Expression of both receptor subtypes was not associated to malignancy, varied between patients, and was not massively increased in association to normal brain issues. In a normal brain, CB1 protein was localized on astroglial and other cell types; in gliomas, it was found on astroglial/glioma cells. CB2 protein was detected on microglial cells/macrophages but rarely on astroglial cells.

Functionally, CB1 receptor agonists decreased elevated cyclic AMP levels and morbidly decreased proliferation of glioma cells, but did not induce cell death. This study concludes that cannabinoid therapy of human gliomas aims to grab at not only receptors on tumor, but also on other cell types. Therefore, complicated and potential adverse events should be considered selectively.

Overall, it is seen that CB1 is the main cannabinoid receptor in human astrocytomas and gliomas, but is not actually elevated as compared to normal problems or other cell types. CB2 is a minor receptor on human astroglial tumor cells, and in solid human astrocytomas/gliomas other cell types may lend a hand to its small level of expression.

Therefore, cannabinoid therapy of human astrocytomas and gliomas may target various cell types, is complex and should be considered with care concerning potential adverse events.

Leave a Reply

Your email address will not be published. Required fields are marked *